OKYO Pharma (FRA:OK10) LT-Debt-to-Total-Asset: 0.00 (As of Sep. 2025)


FRA:OK10 OKYO Pharma Ltd FRA:OK10
23 GF Score
Price €1.36
! 3 Warning Signs
View Full Analysis

What is OKYO Pharma LT-Debt-to-Total-Asset?

OKYO Pharma FRA:OK10 23 LT-Debt-to-Total-Asset is 0.00 as of Sep. 2025. GuruFocus rates FRA:OK10 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. OKYO Pharma's long-term debt to total assests ratio for the quarter that ended in Sep. 2025 was 0.00.

OKYO Pharma's long-term debt to total assets ratio stayed the same from Sep. 2024 (0.00) to Sep. 2025 (0.00).

OKYO Pharma  (FRA:OK10) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

OKYO Pharma LT-Debt-to-Total-Asset Related Terms

OKYO Pharma LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for OKYO Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OKYO Pharma LT-Debt-to-Total-Asset Chart

OKYO Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 0.00

OKYO Pharma Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:OK10
23GF Score
OKYO Pharma Ltd FRA:OK10
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OKYO Pharma LT-Debt-to-Total-Asset Calculation

OKYO Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (A: Mar. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2025 )/Total Assets (A: Mar. 2025 )
=0/3.401
=

OKYO Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2025 is calculated as

LT Debt to Total Assets (Q: Sep. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2025 )/Total Assets (Q: Sep. 2025 )
=0/3.957
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
OKYO Pharma (FRA:OK10) has a LT-Debt-to-Total-Asset of 0.00 as of Sep. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on OKYO Pharma and its competitors.
Is OKYO Pharma's LT-Debt-to-Total-Asset too high?
OKYO Pharma's current LT-Debt-to-Total-Asset is 0.00. Overall, OKYO Pharma has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does OKYO Pharma's LT-Debt-to-Total-Asset compare to ENTX and HRTX?
OKYO Pharma's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on OKYO Pharma and its competitors. OKYO Pharma's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OKYO Pharma stock overvalued right now?
OKYO Pharma (FRA:OK10) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. OKYO Pharma's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For OKYO Pharma (FRA:OK10), the current LT-Debt-to-Total-Asset is 0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OKYO Pharma Business Description

Other Exchanges OKYO:USA
Address 14/15 Conduit Street, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
23GF Score

Get the complete analysis for FRA:OK10

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.36
Price